Table 3.
Between-group comparisons at Week 16: effects of 8-weeks TETA treatment on cardiac function in diabetic cardiomyopathy
| Variable | Control (SHAM) | Diabetic (DIA) | TETA-treated diabetic (TETA-DIA) | P-value † |
|---|---|---|---|---|
|
Body-weight (g) |
489 (466–511) |
313 (283–344) a |
346 (323–368) a |
< 0.0001 |
|
Blood glucose (mM) |
4.7 (4.4-5.1) |
28.8 (27.2-30.4) a |
28.0 (25.7-30.4) a |
< 0.0001 |
|
Heart Rate (bpm) |
396 (384–408) |
317 (306–328) a |
336 (326–346) a, b |
< 0.0001 |
|
LVM (mg) |
785 (744–826) |
732 (698–767) |
737 (688–767) |
0.049 |
|
LVM/BW (mg/g) |
1.61(1.51-1.71) |
2.38 (2.18-2.57) a |
2.12 (1.98-2.27) a, b |
< 0.0001 |
|
CO (ml/min) |
222 (213–232) |
130 (123–136) a |
159 (151–167) a, b |
< 0.0001 |
|
CO/LVM (ml/min.mg) |
0.28 (0.26-0.30) |
0.18 (0.17-0.19) a |
0.22 (0.21-0.23) a, b |
< 0.0001 |
|
LVEF (%) |
72.9 (70.7-75.1) |
62.6 (60.6-64.6) a |
71.1 (68.8-73.4) b |
< 0.0001 |
|
LVEDV (μl) |
770 (753–788) |
656 (628–683) a |
666 (644–687) a |
< 0.0001 |
|
LVEDV/LVM (μl/mg) |
0.99 (0.94-1.03) |
0.90 (0.85-0.95) a |
0.92 (0.87-0.97) |
0.030 |
|
LVESV (μl) |
209 (192–225) |
246 (229–262) a |
193 (177–209) b |
< 0.0001 |
|
LVESV/LVM (μl/mg) |
0.27 (0.25-0.29) |
0.37 (0.35-0.39) a |
0.29 (0.27-0.31) a, b |
< 0.0001 |
|
Stroke Vol (μl) |
562 (540–585) |
410 (388–433) a |
473 (452–495) b |
< 0.0001 |
| Stroke Vol/LVM (μl/mg) | 0.72 (0.68-0.76) | 0.56 (0.53-0.59) a | 0.65 (0.62-0.69) a, b | < 0.0001 |
Values are means (± 95% CI). † One-way ANOVA with post-hoc Tukey’s tests as necessary: a, significantly different from corresponding SHAM value; b, significantly different from corresponding DIA value. Abbreviation: bpm, beats per minute.